Cardiovascular and metabolic side effects of second-generation antipsychotics – narrative review

Since the introduction of second generation antipsychotics (SGA) their use have extended far beyond schizophrenia. With increased usage of these agents, particular attention has been paid to their metabolic and cardiac side effects. This narrative review is an attempt to briefly summarize conclusions from recently published systematic reviews on cardio-metabolic side effects of SGAs. Although no SGA is entirely free of these adverse effects, there are major differences in their prevalence among the medications. Numerous studies have showed particularly unfavorable side effects profile for olanzapine and clozapine. The lack of conclusive data was a major limitation for many studies, especially in those on pediatric population. In article we have also discussed the meanings of these findings, suggested recommendations of cardio-metabolic screening during SGA treatment and side effects management strategies.